Shattuck Labs, a Phase 1 biotech developing novel dual-sided fusion protein therapies for cancer, raised $202 million by offering 11.9 million shares at $17, above the range of $14 to $16. The company offered 1.9 million more shares than anticipated. At pricing, the company raised 35% more in proceeds than expected.
Shattuck Labs plans to list on the Nasdaq under the symbol STTK. Citi, Cowen and Evercore ISI acted as joint bookrunners on the deal.
